Verrica Pharmaceuticals (VRCA) EBT Margin (2021 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly EBT Margin of 209.93% for Q1 2026, up 8073.0% year-over-year from 2.57% in Q1 2025, and down 3.02% quarter-over-quarter from 203.77% in Q4 2025.
Verrica Pharmaceuticals (VRCA) EBT Margin (2021 - 2026) Analysis & Trends
Verrica Pharmaceuticals' EBT Margin history runs 6 years deep, the most recent figure standing at 209.93% for Q1 2026.
- In Q1 2026, EBT Margin rose 8073.0% year-over-year to 209.93%; the TTM figure through Mar 2026 stood at 70.46% (up 59096.0% YoY), while the FY2025 annual figure was 238.9%, up 155054.0% from the prior year.
- EBT Margin for Q1 2026 stood at 209.93%, down from 203.77% in the prior quarter.
- The five-year high for EBT Margin was 17.98% in Q3 2022, with the low at 70750.91% in Q1 2024.
- The 5-year median for EBT Margin is 1216.15% (2023), against an average of 7704.46%.
- The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 4132119 bps in 2024, then soared 7046025 bps in 2025.
- Verrica Pharmaceuticals' EBT Margin stood at 9277.94% in 2022, then surged by 87 bps to 1216.15% in 2023, then slumped by 209 bps to 3761.05% in 2024, then jumped by 95 bps to 203.77% in 2025, then decreased by 3 bps to 209.93% in 2026.
- Business Quant data shows VRCA's EBT Margin at 209.93% in Q1 2026, 203.77% in Q4 2025, and 28.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Verrica Pharmaceuticals | 101.84 Mn | 90.64 Mn | - | -224.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -247.48% |
| Mar 31, 2026 | -209.93% |
| Dec 31, 2025 | -203.77% |
| Sep 30, 2025 | -28.54% |
| Jun 30, 2025 | -9.21% |
| Mar 31, 2025 | -290.67% |
| Dec 31, 2024 | -3,761.05% |
| Sep 30, 2024 | -1,736.55% |
| Jun 30, 2024 | -331.87% |
| Mar 31, 2024 | -70,750.91% |
| Dec 31, 2023 | -1,216.15% |
| Sep 30, 2023 | -848.54% |
| Jun 30, 2023 | -6,038.46% |
| Mar 31, 2023 | -29,429.73% |
| Dec 31, 2022 | -9,277.94% |
| Sep 30, 2022 | 17.98% |
| Jun 30, 2022 | -4,895.33% |
| Mar 31, 2022 | -1,965.20% |
| Mar 31, 2021 | -24.91% |